What it is
A classical Ayurvedic herbomineral vati combining numerous bitter and cleansing herbs with processed mineral ingredients. Classical recipes list kutki, triphala components, neem, guggulu, and several bhasma-class preparations depending on source text.
It ranks first among tracked rasaushadhis in large government prescription audits. Patients often hear "liver tablet" before they hear the classical name.
Where you will encounter it
- Ayurvedic OPD prescriptions for fatty liver, dyslipidemia, metabolic syndrome, or skin complaints
- Ministry standard-treatment discourse as an escalation option in metabolic care
- Patients who say their Ayurvedic doctor gave them a "liver tablet" without reading the classical name
- OTC Ayurvedic lines borrowing the classical name with different processing standards
Further detail
Classical organization
Presentations in liver, skin, metabolism, and digestion can share the classical pattern.
A patient may arrive with fatty-liver labs, stubborn skin disease, metabolic excess, or digestive complaints. Classical prescribing can still reach for the same vati when those presentations are read as one pattern of obstruction, excess, and impaired transformation, not as four separate organ problems.
The recipe is not a modern hepatology tablet, dermatology tablet, or metabolic tablet. That is why the same bottle keeps showing up across lanes, and why an organ-labeled trial cannot speak for every use.
What human research has studied
Modern trials break the formulation back into organ-specific and endpoint-specific questions.
A double-blind randomized study of Arogyavardhini compound plus lifestyle modification reported better metabolic-syndrome components than lifestyle alone over eight weeks. Smaller cohorts exist around fatty liver symptoms and lipid markers.
Those results answer modern endpoint questions. They do not restore the classical pattern map.
What the evidence does not justify
- Treating one organ- or endpoint-specific trial as proof for every lane where the name appears
- Assuming kutki or triphala ingredient evidence proves this herbomineral vati
- Treating audit-table ubiquity as proof for this patient
- Replacing hepatology workups for rising ALT, ascites, or cirrhosis surveillance
Questions worth asking
The useful first question is rarely "Is the liver tablet good?" It is "Which clinical lane is this prescription in?"
- Was this started for liver labs, lipids, glucose, skin, or digestion?
- What is the manufacturer, dose, and duration of use?
- What diabetes, lipid, or liver medicines are you already taking?
- Any recent liver function tests, glucose logs, or new skin or GI symptoms?
Safety and interaction attention
Safety review follows the lane it was started for, plus rasa-class risks.
A patient started for skin may still be taking metabolic medicines. A patient started for fatty liver may already be on lipid-lowering drugs. As a rasaushadhi-class formulation, quality control and heavy-metal testing matter. Additive effects on glucose and lipids are plausible. Pregnancy, chronic liver disease, and polypharmacy contexts deserve explicit review.
Sources
- Padhar BC, Dave AR, Goyal M. Clinical study of Arogyavardhini compound and lifestyle modification in management of metabolic syndrome: a double-blind placebo controlled randomized clinical trial. Ayu. 2019. doi:10.4103/ayu.ayu_79_19
- Gupta YK, Kumar G, Srivastava A, Sharma SK. The hypolipidemic activity of Ayurvedic medicine, Arogyavardhini vati in Triton WR-1339-induced hyperlipidemic rats. J Ayurveda Integr Med. 2013. doi:10.4103/0975-9476.118707
- Sharma R, et al. Prescription audit of selected rasaushadhis in Ayurveda teaching hospitals: a report. J Res Natl Inst Ayurveda. 2024. doi:10.18311/jnr/2024/34139 (prescribing frequency context for Arogyavardhini Vati)
Evidence blocks last reviewed: July 2026.